Outlier [Study As­sess­ment]

posted by NK – India, 2023-06-27 05:57 (744 d 03:11 ago) – Posting: # 23616
Views: 3,493

Dear All,

Please give your valuable inputs.

We have performed 2x2 fasting BE pivotal study for USFDA after seeing pilot study results.

We've noted following from pivotal study data,How to handle this subject’s data? Outlier? Can the regulatory accept the based on Cmax and AUC0-t results?

Can we select the time point manually for Kel calculation instead of best fit method by the tool?

Thanks & Regards
NK


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,428 posts in 4,929 threads, 1,684 registered users;
60 visitors (0 registered, 60 guests [including 34 identified bots]).
Forum time: 09:08 CEST (Europe/Vienna)

To know that we know what we know,
and to know that we do not know what we do not know,
that is true knowledge.    Nicolaus Copernicus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5